Cardiovascular · Small interfering RNA (siRNA)

Lepodisiran

Lepodisiran is an extended-duration small interfering RNA that lowers lipoprotein(a). One 400 mg dose cut Lp(a) by about 94% for six months in Phase 2. Its Phase 3 outcomes trial, with an estimated 17,300 participants, is underway.

Not yet approvedPhase 3 outcomes trial (ACCLAIM-Lp(a)) underway; a single dose lowered Lp(a) by about 94% in Phase 2

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperEli Lilly and Company · Eli Lilly and Company pipeline
Drug typeSmall interfering RNA (siRNA)
TargetLPA gene (apolipoprotein(a)) mRNA
MechanismSilences the LPA gene's messenger RNA in the liver, blocking production of apolipoprotein(a) and lowering lipoprotein(a) for extended periods
Other namesLY3819469

Key points

  • Lepodisiran uses RNA interference to stop the liver making apolipoprotein(a), the protein that defines lipoprotein(a) [Lp(a)].
  • In the 320-patient Phase 2 ALPACA trial, a 400 mg dose reduced Lp(a) by a placebo-adjusted 93.9% from day 60 to day 180.
  • Reductions persisted: with two 400 mg doses, the placebo-adjusted reduction from day 30 to day 360 was 94.8%.
  • ACCLAIM-Lp(a), Lilly's Phase 3 cardiovascular outcomes trial, is active and not recruiting, with an estimated 17,300 participants and estimated primary completion in March 2029 (registry).
  • After pelacarsen's Lp(a)HORIZON trial failed to reduce cardiovascular events in 2026, lepodisiran's outcomes trial carries much more weight as a test of the Lp(a) hypothesis.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Elevated lipoprotein(a) with cardiovascular disease
ACCLAIM-Lp(a) outcomes trial is active, not recruiting. ACCLAIM-CTA, a coronary plaque imaging trial, is recruiting (registry).
Phase 34
3 active · 1 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What lepodisiran is

Lepodisiran is a small interfering RNA (siRNA) developed by Eli Lilly. It targets the messenger RNA of the LPA gene, which carries the instructions for apolipoprotein(a), the protein that turns an ordinary LDL-like particle into lipoprotein(a), or Lp(a). By silencing that RNA in the liver, lepodisiran sharply reduces how much Lp(a) enters the blood. Lilly designed it for an extended duration of action, so it may need very infrequent dosing.

Why the target matters

Lp(a) levels are largely inherited, and genetic studies have linked higher Lp(a) to a greater risk of coronary disease. That human genetic evidence is the main reason several companies are developing Lp(a)-lowering drugs. See What Is Genomics? and the related profiles of olpasiran, pelacarsen, zerlasiran, and muvalaplin.

Clinical evidence

Phase 2: ALPACA

ALPACA randomized 320 participants with a median baseline Lp(a) of 253.9 nmol/L. Participants received lepodisiran at baseline and again at day 180, or placebo. Published in the New England Journal of Medicine in 2025:

Dose Placebo-adjusted change in Lp(a), day 60 to day 180
16 mg −40.8%
96 mg −75.2%
400 mg (pooled) −93.9%

Over the longer window from day 30 to day 360, participants who received 400 mg twice had a placebo-adjusted reduction of 94.8%, and those who received 400 mg once had 88.5%. Serious adverse events occurred in 35 participants, and none was judged by investigators to be related to lepodisiran or placebo. Generally mild injection-site reactions occurred in up to 12% of the highest-dose group.

Phase 3

Trial Purpose Size Status (registry)
ACCLAIM-Lp(a) Whether lepodisiran reduces major adverse cardiovascular events in adults with elevated Lp(a) Estimated 17,300 Active, not recruiting; estimated primary completion March 2029
ACCLAIM-CTA Whether lepodisiran reduces coronary plaque, measured by CT angiography Estimated 252 Recruiting

Scientific perspective

Lepodisiran achieves some of the deepest and longest-lasting Lp(a) reductions reported, from infrequent doses. Whether that prevents heart attacks and strokes has not been tested yet.

That question became much harder in 2026, when pelacarsen lowered Lp(a) by about 78% but did not reduce major cardiovascular events in its 8,323-patient outcomes trial. Lepodisiran differs in two potentially important ways: it lowers Lp(a) more, by over 90%, and its effect lasts much longer. Neither difference guarantees a different outcome. ACCLAIM-Lp(a) will be one of the largest tests of whether near-complete Lp(a) suppression translates into fewer cardiovascular events.

Development perspective

  • Regulatory status: lepodisiran has no FDA approval. Approval to reduce cardiovascular risk would likely depend on a positive ACCLAIM-Lp(a) result.
  • Timing: the registry estimates primary completion in March 2029. Amgen's similar siRNA, olpasiran, has an outcomes trial with an earlier estimated primary completion (March 2028), so the field is likely to see that result first.
  • Historical benchmark: 57.8% of Phase 3 programs have historically reached an application, and about 52% have been approved. This average predates the pelacarsen result and does not account for it.

Competitive context

Lp(a) lowering is now a crowded field, with antisense drugs (pelacarsen), siRNAs (lepodisiran, olpasiran, zerlasiran), and an oral small molecule (Lilly's own muvalaplin). Lilly is unusual in developing two Lp(a) drugs with different mechanisms: an infrequent injection and a daily pill.

Development timeline

  1. Oct 20, 2022ALPACA Phase 2 trial begins (320 participants). Registry
  2. Mar 5, 2024ACCLAIM-Lp(a) Phase 3 cardiovascular outcomes trial begins. Registry
  3. Mar 30, 2025ALPACA results published: placebo-adjusted Lp(a) reduction of 93.9% from day 60 to day 180 with 400 mg. Peer-reviewed
  4. Jun 1, 2026ACCLAIM-CTA, a Phase 3 coronary plaque imaging trial, begins. Registry
  5. Sep 4, 2026Read-across: pelacarsen, a different Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported

What could change the outlook

  • The ACCLAIM-Lp(a) result. The registry estimates primary completion in March 2029, and estimated dates often move.
  • Any amendment to ACCLAIM-Lp(a) after the pelacarsen result, such as a change in size, endpoint, or timing, which will be logged here if it appears in the registry.
  • Results from Amgen's OCEAN(a)-Outcomes trial of olpasiran, a similar siRNA, which is expected to read out earlier and will inform expectations for lepodisiran.
  • Coronary plaque imaging results from ACCLAIM-CTA, which could show whether deep Lp(a) lowering changes atherosclerosis.

Clinical trials

8 registered trials list Lepodisiran as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Elevated lipoprotein(a) with cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06292013
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Phase 3Active, not recruiting17,300 (est.)Mar 2029 (est.)No
ACCLAIM-CTA · NCT07613294
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Phase 3Recruiting252 (est.)Dec 2029 (est.)No
NCT05565742
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
Phase 2Completed320Oct 23, 2023Yes
1 Phase 1 or other early-stage study
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT07914738
A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)
Phase 1Recruiting66 (est.)Mar 2027 (est.)No

Clinical pharmacology and supporting studies

4 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT04914546
A Study of LY3819469 in Healthy Participants
Phase 1Completed66Nov 9, 2022No
NCT06916078
A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Phase 1Completed30Jul 13, 2026No
NCT05932446
A Study to Compare Two Formulations of LY3819469 in Healthy Participants
Phase 1Completed27Nov 7, 2023No
NCT05841277
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
Phase 1Completed26Jan 9, 2024No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Nissen SE, et al. Lepodisiran: a long-duration small interfering RNA targeting lipoprotein(a). New England Journal of Medicine. 2025;392(17):1673–1683.Peer-reviewed
  2. ClinicalTrials.gov. ACCLAIM-Lp(a) (NCT06292013).Registry
  3. ClinicalTrials.gov. ACCLAIM-CTA (NCT07613294).Registry
  4. Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine. 2009;361(26):2518–2528.Peer-reviewed
  5. American Heart Association Newsroom. Lp(a) HORIZON trial results (AHA Scientific Sessions 2026).Scientific meeting
  6. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.